Document Type

Conference Proceeding

Abstract

This evaluation aims to assess whether the health-system is adhering to brivaracetam prescribing restrictions and determine if there are any opportunities for improvement to the current ordering workflow.

Publication Date

12-2023

Comments

Presented at the American Society of Health System Pharmacists (ASHP) Midyear Poster Session (2023).

Disclosure: The authors of this poster have the following to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation: Meghan McNulty, PharmD: Nothing to disclose, Mahmoud Ammar, PharmD, FCCM, BCPS, BCCCP: Nothing to disclose, Paul Ahearn, PharmD, BCPS, BCCCP: Nothing to disclose, Michele Moura, PharmD, BCPS, BCCCP : Nothing to disclose

References

Mumoli L, Palleria C, Gasparini S, et al. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. Drug Des Devel Ther. 2015 Oct 19;9:5719-25

Share

COinS